Roberts Glore & CO Inc Incyte Corp Transaction History

Roberts Glore & CO Inc

$328 Million
Q2 2024

A detailed history of Roberts Glore & CO Inc transactions in Incyte Corp stock. As of the latest transaction made, Roberts Glore & CO Inc holds 8,285 shares of INCY stock, worth $682,186. This represents 0.15% of its overall portfolio holdings.

Number of Shares

8,285

Previous 8,180 1.28%

Holding current value

$682,186

Previous $466,000 7.73%

% of portfolio

0.15%

Previous 0.14%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$51.18 - $63.75 $5,373 - $6,693	105 Added 1.28%	8,285 $502,000
Q4 2023 Feb 12, 2024	SELL	$52.16 - $64.19 $171,345 - $210,864	-3,285 Reduced 28.65%	8,180 $513,000
Q3 2023 Nov 13, 2023	BUY	$57.77 - $65.93 $9,532 - $10,878	165 Added 1.46%	11,465 $662,000
Q2 2023 Aug 14, 2023	BUY	$60.95 - $75.51 $68,568 - $84,948	1,125 Added 11.06%	11,300 $703,000
Q1 2023 May 08, 2023	SELL	$70.23 - $86.01 $10,534 - $12,901	-150 Reduced 1.45%	10,175 $735,000
Q4 2022 Feb 13, 2023	SELL	$67.18 - $84.11 $16,795 - $21,027	-250 Reduced 2.36%	10,325 $829,000
Q4 2021 Feb 11, 2022	BUY	$63.34 - $74.11 $331,901 - $388,336	5,240 Added 98.22%	10,575 $776,000
Q3 2021 Nov 12, 2021	BUY	$68.67 - $84.02 $10,300 - $12,603	150 Added 2.89%	5,335 $367,000
Q1 2021 May 06, 2021	BUY	$76.02 - $100.5 $178,647 - $236,175	2,350 Added 82.89%	5,185 $421,000
Q4 2020 Feb 09, 2021	BUY	$80.74 - $97.7 $24,222 - $29,310	300 Added 11.83%	2,835 $246,000
Q2 2020 Aug 13, 2020	BUY	$74.18 - $108.93 $188,046 - $276,137	2,535 New	2,535 $263,000

Others Institutions Holding INCY

# of Institutions

625

Shares Held

198M

Call Options Held

763K

Put Options Held

476K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $18.3B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Roberts Glore & CO Inc , based on Form 13F filings with the SEC.

News

Stay updated on Roberts Glore & CO Inc with notifications on news.

Account

Roberts Glore & CO Inc Incyte Corp Transaction History